pDONR223-CAMK2D Citations (3)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-CAMK2D

Articles
The Ras-like GTPase Rem2 is a potent inhibitor of calcium/calmodulin-dependent kinase II activity. Royer L, Herzog JJ, Kenny K, Tzvetkova B, Cochrane JC, Marr MT 2nd, Paradis S. J Biol Chem. 2018 Sep 21;293(38):14798-14811. doi: 10.1074/jbc.RA118.003560. Epub 2018 Aug 2. PubMed
Suppression of CaMKIIbeta Inhibits ANO1-Mediated Glioblastoma Progression. Sim KM, Lee YS, Kim HJ, Cho CH, Yi GS, Park MJ, Hwang EM, Park JY. Cells. 2020 Apr 26;9(5). pii: cells9051079. doi: 10.3390/cells9051079. PubMed
Pathological activation of CaMKII induces arrhythmogenicity through TRPM4 overactivation. Hu Y, Kaschitza DR, Essers M, Arullampalam P, Fujita T, Abriel H, Inoue R. Pflugers Arch. 2021 Mar;473(3):507-519. doi: 10.1007/s00424-020-02507-w. Epub 2021 Jan 4. PubMed

If you have published an article using this material, please email us at to have your article added to this page.